DiaMedica Therapeutics (NASDAQ: DMAC) net income
DiaMedica Therapeutics reported a net loss of $32.8m for fiscal 2025; in fiscal 2024 it reported a net loss of $24.4m. Earnings per share were −$0.70.
DiaMedica Therapeutics's best year of the last 9 was fiscal 2017. It reported a loss in 9 of those 9 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$32.8m | — | — | −$0.70 |
| 2024 | −$24.4m | — | — | −$0.60 |
| 2023 | −$19.4m | — | — | −$0.60 |
| 2022 | −$13.7m | — | — | −$0.52 |
| 2021 | −$13.6m | — | — | −$0.65 |
| 2020 | −$12.3m | — | — | — |
| 2019 | −$10.6m | — | — | — |
| 2018 | −$5.7m | — | −1,146.8% | — |
| 2017 | −$4.3m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
DiaMedica Therapeutics net income compared with its sector
By net income for its latest fiscal year, DiaMedica Therapeutics ranks 225th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 223rd | Immix Biopharma | −$29.4m | — |
| 224th | Galectin Therapeutics | −$30.8m | — |
| 225th | DiaMedica Therapeutics | −$32.8m | — |
| 226th | Arbutus Biopharma | −$33.5m | −237.9% |
| 227th | AN2 Therapeutics | −$35.2m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of DiaMedica Therapeutics
- How much did DiaMedica Therapeutics earn in fiscal 2025?
- DiaMedica Therapeutics reported a net loss of $32.8m for fiscal 2025. In fiscal 2024 it reported a net loss of $24.4m.
- What are the earnings per share of DiaMedica Therapeutics?
- They were −$0.70 in fiscal 2025, compared with −$0.60 in fiscal 2024.
- Where does DiaMedica Therapeutics rank in its sector by net income?
- It ranks 225th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for DiaMedica Therapeutics come from?
- From the annual report (Form 10-K) that DiaMedica Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that DiaMedica Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on DiaMedica Therapeutics: the DiaMedica Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.